Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug
In a Phase 2 subgroup of mild-to-moderate Alzheimer’s disease, zervimesine (CT1812) was associated with a 95% slowing of cognitive...
eClinical Tech News
Junshi’s JS001SC Meets Phase 3 Endpoints for Lung Cancer
Non-squamous NSCLC patients treated first line with subcutaneous toripalimab plus chemotherapy achieved non-inferior drug exposure to intravenous toripalimab plus...
Praxis Reveals New Epilepsy Portfolio Data at AES Meeting
Praxis is taking a late-breaker slot at AES 2025 to unveil full results from RADIANT, reporting rapid seizure reductions...
Clearmind Trial Gets Unanimous Approval After Safety Review
Topline from the first dosing cohort: no serious adverse events, generally good tolerability, and strong protocol adherence. An independent...
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule
Climb Bio granted a non-statutory option covering 120,000 shares at an exercise price of $1.76 to a single new...
NCCN Adds Ziftomenib to Acute Myeloid Leukemia Guidelines
Komet-001 reported a 21.4% CR/CRh rate with a median duration of response of five months in adults with relapsed...
CG Oncology to Present Cretostimogene Results at SUO Meeting
No efficacy or safety figures were disclosed ahead of the meeting. CG Oncology signaled that topline data from the...
Profound Medical Unveils AI BPH Module, New Clinical Data
Perioperative data from the CAPTAIN randomized trial indicated lower blood loss, shorter length of stay, reduced post‑operative pain, and...
Silexion Completes SIL204 Toxicology for Pancreatic Cancer
Two-species toxicology for Silexion’s siRNA candidate SIL204 reported no systemic organ toxicity, clearing a key preclinical gate and keeping...
Hutchmed Highlights Data for ESMO Asia, ASH 2025 Meetings
No efficacy or safety figures were disclosed ahead of the meetings, but HUTCHMED will take a broad slate of...